James L. Wittliff, Ph.D., FACB, to Present 'Predicting Breast Cancer Outcome with Gene Expression Signatures on the Ziplex(R) System' at the Association for Molecular Pathology Conference, October 30
...Xceed Molecular will feature Ziplex automated gene-expression system a... conference booth 519 ...WELLESLEY Mass. Oct. 28 /- Xceed Molecular a pioneer i... Visitors to the AMP conference will have a great opportunity to hear...
Date:10/28/2008
Xceed Molecular will feature Ziplex automated gene-expression system at the
conference, booth 519
WELLESLEY, Mass., Oct. 28 /PRNewswire/ -- Xceed Molecular, a pioneer in
the development of cost-effective, easy-to-use gene-expression analysis
systems, announced that renowned breast cancer researcher and Xceed
collaborator, Dr. James L. Wittliff, a professor in the Department of
Biochemistry and Molecular Biology at the University of Louisville, will be
a featured speaker at the Association for Molecular Pathology (AMP) Annual
Meeting. Dr. Wittliff's presentation, "Predicting Breast Cancer Outcome
with Gene Expression Signatures on the Ziplex System" is scheduled from 3
to 4 pm on Thursday, October 30, in the Dallas 1-2 Room. The company also
announced that it will feature its award-winning Ziplex Automated
Gene-Expression System at the conference in booth 519. Currently available
for research use only, the Ziplex System is the first integrated system for
automated gene-expression analysis. It comprises an automated hybridization
workstation, TipChip consumable arrays, reagents, and analysis/reporting
software. The AMP 2008 Annual Meeting and Exhibits takes place October 29
through November 2, 2008, at the Gaylord Texan Resort & Convention Center
in Grapevine, Texas.
"Visitors to the AMP conference will have a great opportunity to hear
Dr. Wittliff's presentation on his exciting research predicting risk of
breast cancer recurrence and to learn how the Ziplex System is integral to
his study process," said Xceed's President and CEO, David Deems. "The
Ziplex System is rapidly becoming the standard platform for the nation's
leading institutions performing translational research. Xceed designed the
Ziplex System with turnkey functionality and significant advances in
automation, array format, parallel sample processing, and analytics to
minimize complexity, user interaction, and variability between users and
sites."
Accor
'/>"/>
SOURCE Xceed Molecular Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price2.
Orchid Cellmark Appoints James F. Smith Chief Financial Officer3.
Immunotec Inc. announces appointment of President & CEO James A. Northrop4.
Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence5.
James Webb Space Telescope marks successful completion6.
IRIDEX Announces James Mackaness Will Be Chief Financial Officer7.
Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board8.
PAREXEL International to Present at Raymond James 29th Annual Institutional Investors Conference9.
Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference10.
Warner Chilcott Reports the Death of Its Director James Andress11.
James W. Backstrom, M.D., Named Chief Medical Officer of Foundation Radiology Group
(Date:7/1/2009)... Johnson & Johnson today a... Department of Molecular Biology at the Max Planck...veries have led to novel cancer therapies includin...e 2009 Dr. Paul Janssen Award for Biomedical Resea...ientists selected Dr. Ullrich, who on September 8 ...
(Date:7/1/2009)... first stimulant to establish duration of efficacy...n in adults with ADHD , , HOLLYWOOD, Fla., July...Nasdaq: SHPGY ), the global specialty biopharmac...ase 3b study that found VYVANSE(R) (lisdexamfetami...cy at 14 hours after administration during a simul...
(Date:7/1/2009)... 1 NeoStem, Inc. (NYSE A...ditional gross funds of over $4 million from insti...her with the $11 million private placement from th... bring the total investment obtained by NeoStem in... In addition, affiliates of Suzhou Erye Pharmaceu...
(Date:7/1/2009)..., Germany, July 1 Gerres...plastic products for the pharma & life,scienc...ions, which are not,part of the MDAX company,s co.... "Through the sale of the Technical Plastics segm...ken a further step in its focus on the core,busin...
Breaking Biology Technology:Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 2Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 3Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 4Video: Axel Ullrich Named Winner of 2009 Dr. Paul Janssen Award for Biomedical Research 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 2Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 3Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 4Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 5Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 6Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 7Study Showed VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment 8NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 2NeoStem Raises Additional Funds from Principals of Suzhou Erye Pharmaceuticals Company Ltd. and U.S. Institutional and Private Investors, Bringing the Total Recent Financings to Over $15 Million; Funds Will Support Expansion Activities in the United State 3Gerresheimer Sells Technical Plastics Business 2... Carl Christensen is a featured speaker at the D... electronic health records. In the last decade, te...rmation has become hot enough to raise a new term,...he Marshfield Clinic , they didn,t wait for that ...dical informatics associations and journals began ...
... In a long-planned departure from its traditional ...c Engineering has contracted with the U.S. Army fo...based in Eau Claire, announced today that it has s...l year 2005. The company has been working with the...nd (CERDEC) to develop a low-cost battery life ind...
... Middleton, Wis. Bone Care International, Inc....llion in profits on $22 million in sales for the q...based drug used to lower abnormally high levels of...ey disease. Gross margins run about 75 percent. , ...y from the same quarter last year, when it reporte...
... Madison, Wis. Representatives of the British C...io and health technology investments, met Wisconsi...pportunities for collaboration. , ,"We,re looking ...imentary technologies," said Frank Phillips, vice ...ulate-General . "Oftentimes the partnership can le...
Other Biology Technology:Carl Christensen says Marshfield Clinic's history gives it an IT edge 2Carl Christensen says Marshfield Clinic's history gives it an IT edge 3Carl Christensen says Marshfield Clinic's history gives it an IT edge 4SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3British, Wisconsin firms explore life-science opportunities together 2British, Wisconsin firms explore life-science opportunities together 3...ve shown for the first time how histatin, the natu...the oral pathogen Candida albicans, the fungus res...Researchers led by Mira Edgerton, D.D.S., Ph.D., d...ne protein called TRK1p, which regulates potassium...nic fungus Candida albicans and allows the cell to...
...sponse to bacterial invasion is to increase nitric...ic oxide synthase. In a study published in the Jou...at the predominantly anti-inflammatory enzyme, end...n nitric oxide production in response to infection...et to treat sepsis, which is caused by overproduct...
... by which hematopoietic stem cells (HSC) give rise...d platelets has now been discovered to depend in l...inding, from an investigator at St. Jude Children,...18 issue of Science. , Mcl-1 blocks the biochemica...ll suicide") of HSCs, according to Joseph Opferman...
...ld Wildlife Fund and its partners in the Internati...nning solutions to prevent the accidental maiming ...sea turtles that become ensnared by fishing nets a...so improving the efficiency of commercial fishing....said Carter Roberts, president and CEO-elect, Worl...
Other Biology News:Discovery may lead to better Candidiasis drug 2Researchers report new pro-inflammatory role for anti-inflammatory enzyme 2Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis 2Protein That Promotes Survival Of Stem Cells Might Be Key To Poor Leukemia Prognosis 3Solutions that reduce death of marine life reeled in by International Smart Gear Competition 2Solutions that reduce death of marine life reeled in by International Smart Gear Competition 3Request Info
...munogen: Synthetic peptide derived from the intern...y: Specific for the junctophilin-1 protein. React...keletal muscle homogenates frozen mouse brain and ...lotting Immunohistochemistry(froz) Immunofluoresce...
...w Stem Cell Antibody Panels to its expanding line ...ll Marker Antibody Panel (Catalog # SC008) contain...nog, Oct-3/4, SSEA-1 and SSEA-4. The Human Embryon... SC009) contains antibodies against: CD9, E-Cadher...
Epstein-Barr Virus (EBV) (EBNA-1)
Biology Products: